In CRC, Cdk5 functions as a tumor promoter via modulating the extracellular receptor kinase 5 (ERK5)—activator protein 1 (AP-1) axis [13] and it has been associated with oxaliplatin resistance acquisition [14]. This evidence concerns the gene CDK5 and colorectal carcinoma.